[
  {
    "ts": "2025-06-28T14:05:10+00:00",
    "headline": "Biogen highlights ‘promising’ results for higher-dose nusinersen in SMA trials",
    "summary": "Biogen (BIIB) announced new data that it says reinforce the clinical impact of nusinersen across a broad spectrum of individuals affected by spinal muscular atrophy. These latest findings from Part C of the DEVOTE trial evaluating a higher dose regimen of nusinersen and the NURTURE trial which evaluated the approved 12 mg regimen — SPINRAZA — in clinically presymptomatic SMA were presented at the SMA Research & Clinical Care Meeting hosted by Cure SMA in Anaheim, Calif. Biogen’s applications for",
    "url": "https://finance.yahoo.com/news/biogen-highlights-promising-results-higher-140510211.html",
    "source": "TipRanks",
    "provider": "yfinance",
    "raw": {
      "id": "6abccf58-5c6a-3be8-b8bc-a9a8399aec13",
      "content": {
        "id": "6abccf58-5c6a-3be8-b8bc-a9a8399aec13",
        "contentType": "STORY",
        "title": "Biogen highlights ‘promising’ results for higher-dose nusinersen in SMA trials",
        "description": "",
        "summary": "Biogen (BIIB) announced new data that it says reinforce the clinical impact of nusinersen across a broad spectrum of individuals affected by spinal muscular atrophy. These latest findings from Part C of the DEVOTE trial evaluating a higher dose regimen of nusinersen and the NURTURE trial which evaluated the approved 12 mg regimen — SPINRAZA — in clinically presymptomatic SMA were presented at the SMA Research & Clinical Care Meeting hosted by Cure SMA in Anaheim, Calif. Biogen’s applications for",
        "pubDate": "2025-06-28T14:05:10Z",
        "displayTime": "2025-06-28T14:05:10Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/tipranks_452/8948b64e92d23cb05c63afbc8ed98e4c",
          "originalWidth": 192,
          "originalHeight": 192,
          "caption": "https://www.tipranks.com/news/the-fly/biogen-highlights-promising-results-for-higher-dose-nusinersen-in-sma-trials-thefly",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/T3YDggAmmLOUAxzdgVEz.g--~B/aD0xOTI7dz0xOTI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/8948b64e92d23cb05c63afbc8ed98e4c.cf.webp",
              "width": 192,
              "height": 192,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/bkNUtFmn3fdeUa0HVgGp.g--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/tipranks_452/8948b64e92d23cb05c63afbc8ed98e4c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "TipRanks",
          "url": "https://www.tipranks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/biogen-highlights-promising-results-higher-140510211.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biogen-highlights-promising-results-higher-140510211.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-06-28T08:16:34+00:00",
    "headline": "Biogen Advances Once-Yearly SMA Therapy Salanersen to Phase 3 After Positive Phase 1 Results",
    "summary": "Biogen Inc. (NASDAQ:BIIB) is one of the most undervalued US stocks according to analysts. On June 25, Biogen announced positive topline results from an interim analysis of its Phase 1 study for salanersen (BIIB115/ION306), which is an investigational antisense oligonucleotide/ASO for treating spinal muscular atrophy/SMA. Based on these encouraging findings, Biogen is engaging with global […]",
    "url": "https://finance.yahoo.com/news/biogen-advances-once-yearly-sma-081634301.html",
    "source": "Insider Monkey",
    "provider": "yfinance",
    "raw": {
      "id": "3a6a6fd0-e82c-37e2-835a-3c6974e8a788",
      "content": {
        "id": "3a6a6fd0-e82c-37e2-835a-3c6974e8a788",
        "contentType": "STORY",
        "title": "Biogen Advances Once-Yearly SMA Therapy Salanersen to Phase 3 After Positive Phase 1 Results",
        "description": "",
        "summary": "Biogen Inc. (NASDAQ:BIIB) is one of the most undervalued US stocks according to analysts. On June 25, Biogen announced positive topline results from an interim analysis of its Phase 1 study for salanersen (BIIB115/ION306), which is an investigational antisense oligonucleotide/ASO for treating spinal muscular atrophy/SMA. Based on these encouraging findings, Biogen is engaging with global […]",
        "pubDate": "2025-06-28T08:16:34Z",
        "displayTime": "2025-06-28T08:16:34Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/insidermonkey.com/8095fdfd16ed3bef236befbd7ca2428c",
          "originalWidth": 1456,
          "originalHeight": 816,
          "caption": "Biogen Advances Once-Yearly SMA Therapy Salanersen to Phase 3 After Positive Phase 1 Results",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/6ixRM3d_RV3w5hCozODMpg--~B/aD04MTY7dz0xNDU2O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/insidermonkey.com/8095fdfd16ed3bef236befbd7ca2428c.cf.webp",
              "width": 1456,
              "height": 816,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/HIrwEXIPFTzVGiKAPI9LJA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/insidermonkey.com/8095fdfd16ed3bef236befbd7ca2428c.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Insider Monkey",
          "url": "http://www.insidermonkey.com"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/biogen-advances-once-yearly-sma-081634301.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/biogen-advances-once-yearly-sma-081634301.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "BIIB"
            },
            {
              "symbol": "IONS"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]